skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15370

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia



Review

(5429) Total Article Views


Authors: Lisa M Lima, Martha Arellano, Stacie Holloway, et al

Published Date September 2010 Volume 2010:1 Pages 221 - 225
DOI: http://dx.doi.org/10.2147/JBM.S7158

Lisa M Lima, Martha Arellano, Stacie Holloway, Marian Shepard, Stephanie McMillan, Hanna Jean Khoury
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.

Keywords: dasatinib, resistant CML, outcomes


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Jean Khoury


Readers of this article also read: